6月25日,云顶新耀宣布,其自免产品伊曲莫德在韩国的新药上市许可申请(NDA)已获受理,用于治疗中重度活动性溃疡性结肠炎(UC)患者。此前,该药已在美国、欧盟、加拿大、澳大利亚、英国、瑞士、以色列以及中国澳门和新加坡获得新药上市批准,在国内也已提交上市申请。此次在韩国获NDA受理,意味着云顶新耀在亚洲市场的又一重要准入进展。溃疡性结肠炎(UC)是一类目前病因尚未完全明确的肠道慢性炎症性疾病,主要...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.